“Biosimilars offer significant value to patients, providers and payers, increasing the number of treatment options available to patients across many disease areas at a reduced cost to the healthcare system. The Justices’ unanimous ruling on the notice of commercial marketing will help expedite patient access to life-enhancing treatments. We also appreciate the clarity provided on the patent dance, which will help the biosimilars industry move forward,” said Carol Lynch, Global Head of Biopharmaceuticals, Sandoz. “As the global leader in biosimilars, it is our responsibility to help …
“Biosimilars offer significant value to patients, providers and payers, increasing the number of treatment options available to patients across many disease areas at a reduced cost to the healthcare system. The Justices’ unanimous ruling on the notice of commercial marketing will help expedite patient access to life-enhancing treatments. We also appreciate the clarity provided on the patent dance, which will help the biosimilars industry move forward,” said Carol Lynch, Global Head of Biopharmaceuticals, Sandoz. “As the global leader in biosimilars, it is our responsibility to help …
- Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020
- Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services
- Poised for next growth phase, anticipated to begin in 2018
Boston, May 31, 2017 – Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving …
- Building depth across key therapeutic areas with 12 potential blockbusters in late stage development and 40 potential filings in US and EU between 2017-2020
- Focused and taking steps to become stronger and more integrated through centralized manufacturing, development and business services
- Poised for next growth phase, anticipated to begin in 2018
Boston, May 31, 2017 – Today Novartis holds its fourth annual Meet Novartis Management event at its research headquarters in Cambridge, MA, giving …
- Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®†
- Comprehensive data packages demonstrate each biosimilar matches its respective reference medicine in terms of quality, efficacy and safety
- These regulatory submissions follow soon after two positive CHMP opinions** for Sandoz biosimilars etanercept and rituximab further reinforcing Sandoz immunology pipeline and the broader Novartis immunology portfolio
…
- Net sales grew 2% (cc, -1% USD), as growth drivers more than offset Gleevec/Glivec impact
- Cosentyx (USD 410 million, +136% cc) showing strong growth in all three indications
- Entresto (USD 84 million) steadily growing with better access in US and EU
- Gilenya (USD 722 million, +5% cc) grew mainly driven by volume
- Excluding Gleevec/Glivec, Oncology grew +7% (cc) driven mainly by Promacta/Revolade, Jakavi, Tafinlar + Mekinist and Tasigna
- Core[1] operating income down 5% (cc) due to generic erosion and increased investments, mainly …
- Sandoz receives positive CHMP opinions for biosimilars rituximab and etanercept to treat immunological diseases. Biosimilar rituximab also recommended to treat blood cancers
- Comprehensive data packages, confirming Sandoz biosimilars rituximab and etanercept match their respective reference medicines, were the basis for CHMP decisions
- Subject to EC** approval, Sandoz market leadership position extended as the only company to have five approved biosimilars in Europe1
Holzkirchen, April 21, 2017 – Sandoz …
- Total investment of EUR 105 million in Prevalje site reinforces commitment to largest Sandoz business, Anti-Infectives, and single largest global product, broad-spectrum antibiotic amoxicillin-clavulanic acid.
- The investment will bring 150 new jobs, more than doubling the number of employees at Prevalje over six years.
- The project, scheduled for completion in 2019, will be the largest Novartis investment in Slovenia to date.
Prevalje, April 11, 2017 – A foundation stone for the new production plant for a broad- …
- Sandoz Scientific Standalone event — “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
- Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event
- Enhanced digital training can help improve health outcomes for patients
Holzkirchen, March 20, 2017 – …
- Sandoz Scientific Standalone event — “Reach Targets, Save Lives” – aims at increasing access to information in the field of cardiovascular therapies in Central & Eastern Europe and Middle East & Africa (CEEMEA)
- Lectures by leading cardiologists and internal medicine specialists will be recorded and offered for re-use across the region following the live event
- Enhanced digital training can help improve health outcomes for patients
Holzkirchen, March 20, 2017 – …
Follow us on Facebook
ADDRESS – ZIMBABWE
Suite 204, Block 1
Long Cheng Plaza
Mutley Bend, Belvedere
Harare, Zimbabwe
ADDRESS – ZAMBIA
Plot 43504
Apex Chalala
Off Kasama Road
Lusaka Zambia